As the new European Parliament meets for its inaugural session in Strasbourg, Belgium, EuropaBio has published its
Biotechnology Industry Manifesto 2019. The manifesto calls upon EU decision makers to reset the ambition for a healthier, more resource efficient, technology driven Europe.
Biotechnology is already a transformative EU asset, says EuropaBio, significantly addressing unmet medical needs, enabling smarter, more efficient use of natural resources, reducing greenhouse gas emissions and improving the quantity and quality of food and feed. But huge potential remains untapped for delivering new and innovative solutions to the United Nations Sustainable Development Goals for 2030.
EuropaBio Secretary General, Joanna Dupont-Inglis commented: “Time is now of the essence in addressing the grand challenges facing Europe and the wider world. The EU Biotech community is already fully engaged in this work and, with the right political support and regulatory framework, can play an even greater role. For this, we need to foster an ecosystem which encourages innovation, builds trust, protects IP, attracts and unlocks investment and develops a coherent EU life sciences and biotechnology strategy.”
EuropaBio is calling on the EU’s new political leadership “to be bold and decisive in its decision making, fostering innovative biotechnology to benefit people and planet.”
Read the full Biotechnology Industry Manifesto 2019
.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.